Understanding the factors affecting global political priority for controlling sexually transmitted infections: a qualitative policy analysis

Dadong Wu, Nicola Low, Sarah J Hawkes

ABSTRACT

Introduction Sexually transmitted infections (STIs) are a significant public health challenge, but there is a perceived lack of political priority in addressing STIs as a global health issue. Our study aimed to understand the determinants of global political priority for STIs since the 1980s and to discern implications for future prioritisation.

Methods Through semistructured interviews from July 2021 to February 2022, we engaged 20 key stakeholders (8 women, 12 men) from academia, United Nations agencies, international non-governmental organisations, philanthropic organisations and national public health agencies. A published policy framework was employed for thematic analysis, and findings triangulated with relevant literature and policy documents. We examined issue characteristics, prevailing ideas, actor power dynamics and political contexts.

Results A contrast in perspectives before and after the year 2000 emerged. STI control was high on the global health agenda during the late 1980s and 1990s, as a means to control HIV. A strong policy community agreed on evidence about the high burden of STIs and that STI management could reduce the incidence of HIV. The level of importance decreased when further research evidence did not find an impact of STI control interventions on HIV incidence. Since 2000, cohesion in the STI community has decreased. New framing for broad STI control has not emerged. Interventions that have been funded, such as human papillomavirus vaccination and congenital syphilis elimination have been framed as cancer control or improving newborn survival, rather than as STI control.

Conclusion Globally, the perceived decline in STI control priority might stem from discrepancies between investment choices and experts’ views on STI priorities. Addressing STIs requires understanding the intertwined nature of politics and empirical evidence in resource allocation. The ascent of universal health coverage presents an opportunity for integrated STI strategies but high-quality care, sustainable funding and strategic coordination are essential.

INTRODUCTION

Setting priorities within health services is a political process—driven not just by evidence of the burden of any particular condition, but also by the power of policy actors, prevailing ideas and the emergence of political priority in controlling STIs.
of windows of opportunity.\textsuperscript{1, 2} At the global level, political priority refers to ‘the degree to which international and national political leaders actively give attention to an issue and back up that attention with financial, technical and human resources that are commensurate with the issue’s severity’.\textsuperscript{3} The relative position of any health issue on the global health agenda also reflects the importance of social values and issue-framing, which drive the attention paid to the issue.\textsuperscript{4} There is a perception that global attention to the control of sexually transmitted infections (STIs) other than HIV is insufficient\textsuperscript{5} and has declined since the late 1980s and 1990s,\textsuperscript{6} when STI control was promoted as a means to lower the transmission of HIV.\textsuperscript{7, 8} The term STIs comprises a range of infections, many of which are common and, together, cause substantial morbidity and mortality. The WHO estimates that there were 374 million new cases of four curable infections (chlamydia, gonorrhoea, syphilis and trichomoniasis) in 2020.\textsuperscript{10} According to the 2019 Global Burden of Disease (GBD) study, non-HIV STIs were associated with 8.57 million disability-adjusted life-years, of which 62.3\% can be attributed to congenital syphilis.\textsuperscript{11} The GBD estimates of STI burden would increase if conditions such as human papillomavirus (HPV) infection, which causes most cervical cancer\textsuperscript{12} and the contribution of STIs to conditions such as preterm birth, were included.

The question of whether and why STI control really has dropped down the policy agenda has not been examined systematically but is of interest and importance for those seeking to ensure appropriate and fair levels of resource allocation to achieve goals of STI control because resources are limited. Ideally, this task should be a collaborative effort, shared between ‘the Ministry of Health and the entire health stakeholder community’ including citizens and health system providers.\textsuperscript{13} One indicator of relative priority is financial resource allocation. Grollman et al reported that the four curable STIs accounted for 16\% (US$699.3 million) of total official development assistance and grants from the Bill & Melinda Gates Foundation allocated to reproductive, maternal, newborn and child health in 2003. However, this percentage declined to 1\% by 2006 and remained at this level, amounting to US$83 million by 2013.\textsuperscript{14} WHO estimated a need of US$18.200 million for global STI prevention and control efforts in over 100 low-income and middle-income countries (LMICs) between 2016 and 2021.\textsuperscript{15} It is not yet clear what proportion of this amount was allocated, but there are thought to be significant funding gaps, from both official development assistance allocations and contributions at the national ministry level in many settings.\textsuperscript{16} Some specific interventions have gained priority on the global health agenda. For example, the Global Fund to Fight AIDS, Tuberculosis and Malaria invested US$3.12 billion between 2003 and 2010 in maternal, newborn and child health, which includes prevention of mother-to-child transmission (PMTCT) of syphilis.\textsuperscript{17} Gavi, the global vaccine alliance, committed up to US$500 million to support the introduction of HPV vaccination in 40 LMICs from 2016 to 2020.\textsuperscript{18} Also, the Global Antibiotic Research and Development Partnership invested €75 million in 2021 into developing new treatments for antimicrobial-resistant infections, including gonorrhoea.\textsuperscript{19}

In this paper, we seek to understand the determinants of global political priority for STIs over the past four decades and to discuss the implications for future priority setting.

**METHODS**

**Study design**

To undertake this qualitative policy analysis, we triangulated evidence from interviews with key informants and from a review of published studies, organisation reports and grey literature. We report our findings according to the Consolidated Criteria for Reporting Qualitative Research\textsuperscript{20} and Sex and Gender Equity in Research guidelines.\textsuperscript{21}

**Policy framework**

Analysis and synthesis of qualitative data were guided by a conceptual framework developed by Shiffman and Smith to determine global political priority of health issues.\textsuperscript{3} The framework comprises four categories, which cover eleven determinants of political priority (table 1) and has been applied to the analysis of a number of global health initiatives, such as maternal mortality reduction, mental health, global surgery, emergency care and early childhood development.\textsuperscript{3, 22–25}

The category of issue characteristics looks at the nature of the issue itself. Problems that can be measured by credible indicators are more likely to attract attention as policy-makers and funders will have information to confirm their severity and monitor progress.\textsuperscript{26} Moreover, policy-makers are more inclined to address a problem if there are effective interventions.\textsuperscript{27} The category of ideas examines how an issue and its solution are understood and portrayed both within the policy community and publicly—the frame.\textsuperscript{26} Actor power considers the performance of networks comprising individuals from various organisations who share a common policy concern. The

---

**Table 1** The four categories of determinants of global political priority

<table>
<thead>
<tr>
<th>Category</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Issue characteristics</td>
<td>Features of the problem</td>
</tr>
<tr>
<td>Ideas</td>
<td>The ways in which those involved with the issues understand and portray it</td>
</tr>
<tr>
<td>Actor power</td>
<td>The strength of the individuals and organisations concerned with the issue</td>
</tr>
<tr>
<td>Political contexts</td>
<td>The environments in which actors operate</td>
</tr>
<tr>
<td>From Shiffman and Smith.\textsuperscript{3}</td>
<td></td>
</tr>
</tbody>
</table>
membership, structure and organisation of these policy communities determine their impact on the policy processes. Global and national policy communities function more effectively in shaping policy agendas where influential entrepreneurs or strong guiding institutions emerge to lead them. Additionally, initiatives that connect with grassroots organisations in civil society are more likely to obtain policy attention. Finally, the category of political contexts explores the environment in which actors operate, especially ‘policy windows’ which refer to the key moments when conditions align favourably for certain issues, as well as global governance structure in the sector.

Data collection

Informant interviews

We conducted a stakeholder mapping in June 2021 to guide identification of potential informants, based on our experiences in STI-related research and relevant publications. We also followed informants’ referrals across multiple domains, including funders, policy-makers, advocates and researchers. We aimed for gender and geographical balance in our selection of interview respondents. Potential informants were contacted using a standardised email, which explained the purpose of the study, potential risks, and how privacy and confidentiality would be maintained. All respondents signed a consent form allowing audio recording of interviews and had the opportunity to ask questions before the start of the interview (online supplemental file 1A,B). Semi-structured interviews were used, following a general interview guide based on the Shiffman and Smith framework. Owing to COVID-19 international travel restrictions, in-person interviews were not feasible. DW, an early-career female researcher, with experience in health policy analysis and STI control, conducted all discussions in English via online platforms. The researcher had no prior personal relationships with the informants. Each interview involved only the interviewer and participant and lasted 30–90 min, during which notes were taken. No repeat interviews were conducted. Questions were tailored for each informant based on their position and responsibilities around STI control. If feasible, they were also invited to comment on anonymised answers of other respondents. To assess power dynamics and their evolution over time, informants were asked to identify key actors shaping the global health agenda and influencing resource allocation. At the end of each interview, they were queried on the most influential factor for prioritisation of STIs. Respondent recruitment persisted until theoretical saturation was achieved, that is, when all factor themes had been identified and additional interviews were unlikely to reveal new information.

The recorded interviews were transcribed and all materials were stored digitally in password-protected computers and deidentified during data analysis. Transcripts were not sent back to informants, but some were contacted to ensure the accuracy of quotes.

Literature review

We performed a literature review concurrently with the interviews. We collected data about global policies and practices for STI control by searching established databases and websites of organisations involved in advocating for and/or financing STI control. We searched PubMed and Web of Science to identify relevant studies published in English between 1980 and 2022. The search strings combined MeSH headings 2022 (“sexually transmitted diseases”, “syphilis”, “gonorrhea”, “chlamydia infections”, “trichomonas”, “herpes genitalis”, “human papillomavirus”) and free-text terms (“policy”, “priority”, “salience”, “prioritisation”, “agenda setting”, “decision making”, “policy making”). We initially found 3677 publications and, through a process of title and abstract screening, narrowed these down to 26 relevant articles. Furthermore, we reviewed specific articles pertinent to STI control identified in our previous research. We also searched the WHO Library and websites of three United Nations agencies (Joint United Nations Programme on HIV/AIDS (UNAIDS), United Nations Children’s Fund, United Nations Population Fund), the Global Fund for AIDS, TB and Malaria, and the Bill & Melinda Gates Foundation. In addition, some informants directed us to particular projects and studies. We selected studies and documents based on their relevance to the political prioritisation of STI control.

Data analysis and synthesis

Using the four categories and eleven factors from the Shiffman and Smith framework as main themes and subthemes, we conducted an iterative thematic analysis. The NVivo software (V.11) was employed to organise and analyse the interview transcripts. A single researcher (DW) coded all the transcripts and identified themes regarding determinants of global political priority for STIs. Data sources triangulation was used to cross-verify information from different types of stakeholders, and to compare and contextualise findings from interviews with those from published studies and organisation reports. Documents were reviewed continuously during this process to trace changes in organisational interests on STIs, identify issue framings and pinpoint key events in the policy process. To report the interview findings, we assigned each key informant a number and cited relevant literature and documents from our review to give a broader interpretation and contextualisation of the interview findings. During the analysis, the findings were discussed via online meetings with other researchers (NL and SH) and at a face-to-face meeting in June 2022 involving a multidisciplinary project team (online supplemental file 2).

Patient and public involvement

This study was part of a multidisciplinary project examining the political prioritisation of the prevention and control of STIs (online supplemental file 2). No patients participated in the design or conduct of this
policy analysis. As part of the larger project, we did interview pregnant women and healthcare workers in Papua New Guinea and Zambia to explore civil society mobilisation and advocacy and we report on their priorities, experiences or preferences separately.

RESULTS
From July 2021 to February 2022, we contacted 34 potential informants, of whom 23 responded and 3 declined to be interviewed (59% acceptance rate). Of the 20 respondents, 8 were women, only 2 were originally from LMICs and 15 first became involved in STI control and prevention before 2000 (table 2). The respondents came from 10 countries (Australia, Bangladesh, Belgium, France, Italy, Netherlands, Switzerland, Zimbabwe, UK, US) and have worked in different types of organisations, including United Nations agencies (WHO headquarters or regional offices, UNAIDS), national public health agencies, development partners (bilateral assistance programmes, private philanthropic funders), international non-governmental organisations (NGOs) and academia.

We report our findings about factors affecting actor power, ideas, political contexts and issue characteristics, particularly contrasting the periods before and since 2000. This time frame emerged from the interview data as the approximate timing of an apparent shift in donor attention on STI control (figure 1).

### Issue Characteristics

**Before 2000**
The World Bank 1993 World Development Report stated that STIs, excluding HIV, accounted for 9% of the disease burden among adult women and 2% among adult men.² This report emphasised the cost-effectiveness of treating bacterial STIs, playing a crucial role in raising awareness about the burden of STIs and the importance for addressing their control (figure 1). These findings contributed to STIs being portrayed as a ‘tremendous public health problem’ deserving policy, donor and research attention in the early 1990s (Informant, I4, I8). Syndromic management to treat the most common causes of STI symptoms gained ground at the primary care level in Africa, where there was little financial investment and no simple and accurate diagnostic tests for most STIs (I5, I6, I7, I8, I13 and I14).³⁶ As a respondent stated, this

…pointed to the necessity of non-specialist approaches, so much more decentralised approaches to STI diagnosis and

<table>
<thead>
<tr>
<th>Informant</th>
<th>Gender</th>
<th>First involvement in STI control</th>
<th>Type of primary affiliation</th>
<th>Income category of country of origin</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Man</td>
<td>Before 2000</td>
<td>Academia</td>
<td>High</td>
</tr>
<tr>
<td>2</td>
<td>Man</td>
<td>Before 2000</td>
<td>United Nations agency</td>
<td>Lower middle</td>
</tr>
<tr>
<td>3</td>
<td>Woman</td>
<td>Before 2000</td>
<td>Academia</td>
<td>High</td>
</tr>
<tr>
<td>4</td>
<td>Man</td>
<td>Before 2000</td>
<td>Bilateral assistance programme</td>
<td>High</td>
</tr>
<tr>
<td>5</td>
<td>Woman</td>
<td>Before 2000</td>
<td>Academia</td>
<td>High</td>
</tr>
<tr>
<td>6</td>
<td>Man</td>
<td>Before 2000</td>
<td>Academia</td>
<td>High</td>
</tr>
<tr>
<td>7</td>
<td>Woman</td>
<td>Before 2000</td>
<td>Philanthropic funder</td>
<td>High</td>
</tr>
<tr>
<td>8</td>
<td>Man</td>
<td>Before 2000</td>
<td>United Nations agency</td>
<td>Lower middle</td>
</tr>
<tr>
<td>9</td>
<td>Man</td>
<td>Before 2000</td>
<td>International NGO</td>
<td>High</td>
</tr>
<tr>
<td>10</td>
<td>Man</td>
<td>After 2000</td>
<td>Philanthropic funder</td>
<td>High</td>
</tr>
<tr>
<td>11</td>
<td>Man</td>
<td>Before 2000</td>
<td>United Nations agency</td>
<td>High</td>
</tr>
<tr>
<td>12</td>
<td>Man</td>
<td>After 2000</td>
<td>International NGO</td>
<td>High</td>
</tr>
<tr>
<td>13</td>
<td>Man</td>
<td>Before 2000</td>
<td>Academia</td>
<td>High</td>
</tr>
<tr>
<td>14</td>
<td>Woman</td>
<td>Before 2000</td>
<td>Academia</td>
<td>High</td>
</tr>
<tr>
<td>15</td>
<td>Man</td>
<td>Before 2000</td>
<td>Academia</td>
<td>High</td>
</tr>
<tr>
<td>16</td>
<td>Woman</td>
<td>Before 2000</td>
<td>Academia</td>
<td>High</td>
</tr>
<tr>
<td>17</td>
<td>Man</td>
<td>After 2000</td>
<td>International NGO</td>
<td>High</td>
</tr>
<tr>
<td>18</td>
<td>Woman</td>
<td>Before 2000</td>
<td>Academia</td>
<td>High</td>
</tr>
<tr>
<td>19</td>
<td>Woman</td>
<td>After 2000</td>
<td>National public health agency</td>
<td>High</td>
</tr>
<tr>
<td>20</td>
<td>Woman</td>
<td>After 2000</td>
<td>United Nations agency</td>
<td>High</td>
</tr>
</tbody>
</table>

NGO, non-governmental organisation; STI, sexually transmitted infection.
management, and, in doing so, helped to raise the profile...of this public health problem. (I4)

Since 2000

Estimates of global STI burden have been contested by some informants (I2, I11, I18 and I20) for two reasons: First, the underlying basis of the estimates is uncertain because data such as prevalence, incidence, mortality and antimicrobial resistance patterns of STIs remain unknown in many settings with poor information collection and surveillance. Second, many burden assessments have not included all STI-associated impacts such as HPV-related cancers and neonatal morbidity and mortality. Informants attributed the persisting "unclear magnitude" of STIs worldwide to a chronic lack of funding for epidemiological research (I2, I4, I7, I8, I16 and I20). As one mentioned:

[T]o some extent, you have these...self-reinforcing systems or vicious circles where the lack of funding results in a lack of data and a lack of data makes everybody think that there is no problem, and that leads to even less funding. (I4)

Evidence from the late 1990s raised concerns about the effectiveness and cost-effectiveness of syndromic management as a means to treat STIs, further decreasing the policy options available for STI control. Two respondents highlighted the lack of clear interventions (I11 and I19), noting that WHO set 'aspirational' targets, such as reducing syphilis and gonorrhoea incidence by 90% by 2030, without providing countries with specific guidance on how to achieve these goals. Many informants attributed the neglect of STIs to the dearth of affordable diagnostics and treatments in LMICs (I5, I7, I11, I13, I14 and I18), leaving syndromic management as the main intervention for STI control, despite its problems. Congenital syphilis control is an exception because there is robust evidence of the effectiveness and cost-effectiveness of screening in pregnancy and scaling up is being facilitated by innovative tools, such as dual rapid tests for HIV and syphilis.

There’s a renewed interest in STD control, however, we are still stuck with the absence of point-of-care testing...So the problem has not gone away and certainly not been solved. (I15)

Ideas and issue framing

Before 2000

In the 1980s and early 1990s as evidence of the substantial impact of HIV on people and economies became clear, there was an active hunt for affordable and effective solutions to the HIV pandemic. Epidemiological synergy between STIs and HIV was documented and randomised controlled trials to examine the effect of interventions to control STIs on HIV transmission were designed and launched. The first published trial in 1995, found that communities provided with STI syndromic management in Mwanza Region, Tanzania had a lower incidence of HIV infection than communities without STI control (the trial is widely referred to as ‘the Mwanza trial’). Many respondents agreed that the Mwanza trial findings greatly enhanced the prioritisation of STIs (I2, I3, I4, I5, I6, I7, I8 and I9). Syndromic management was then portrayed as a means of tackling the HIV epidemic (figure 1), including as part of an integrated reproductive health programme reaching women in family planning and antenatal clinics. (I3)

However, another randomised controlled trial, published in 1998, found no impact on HIV transmission of mass antimicrobial treatment for STIs at the village level in Rakai, Uganda (referred to as ‘the Rakai trial’).
trial’). Additionally, two informants noted that the advent of highly active antiretroviral therapy at the Vancouver AIDS conference in 1996 further reduced the relevance of management of other STIs in HIV control among global actors (I3 and I16). This led to growing scepticism about prioritising STI management as part of HIV control, especially among major donors (I1, I2, I3, I4, I5, I7, I9 and I19). Consequently, consensus among global actors diminished, prompting major donors to withdraw resources from STI management initiatives (I4, I5 and I9).

PEPFAR [the United States President’s Emergency Plan for AIDS Relief] did not put money into it anymore. PEPFAR put all its money into HIV prevention, into antiretroviral treatment, male circumcision, and prevention of mother-to-child transmission. (I5)

Since 2000
The findings of the Rakai trial in 1998, along with other trials of syndromic management and suppression of herpes simplex published since 2000, changed the balance of scientific opinion about the linkage between STI management and HIV control. This shift was compounded by the STI community’s failure to establish alternative framings that were powerful enough to sustain policy attention (figure 1). As commented:

The linkage to HIV was our biggest chance to have an integrated approach to control all the STIs and HIV and I think we placed too much emphasis on that. So that when the data didn’t support this as a co-intervention for prevention of HIV, there was a loss of interest. (I19)

The informants shared the view that prioritisation of non-HIV STIs since 2000 has been hindered by the popular perception that they are treatable, not fatal and have a significantly lower burden than other major infectious diseases, like HIV and tuberculosis (I5, I8, I13, I14, I18 and I20), as well as the associated stigma of infections transmitted through sexual activity (I1, I4, I8, I9 and I20). Congenital syphilis was identified as an exception (I18 and I20), as well as the associated stigma of infections and contacts and were able to allocate funds to STIs. For example, in 1987, both of which, according to Lush et al, hosted high profile meetings, culminating in a consensus statement with recommendations for coordinating AIDS and STI programmes. Two informants (I2 and I6) pointed to the strong leadership of GPA in promoting STI control in the 1990s, which helped secure support from key funders, such as the US President’s Emergency Plan for AIDS Relief, US Agency for International Development, Department for International Development, UK, the World Bank and others.

The GPA became UNAIDS in 1996 and the funds were used to assist national governments in most African countries to introduce syndromic management guidelines through HIV control programmes (I2) and maternal and child health or family planning programmes. This process was facilitated by the active involvement of several international NGOs, such as Family Health International and the Population Council (I7 and I9). As one respondent put it:

...HIV and STI colleagues at WHO would be amongst the most influential in terms of international policy in this area at that time. (I6)

The successful advocacy during this period was also attributed to the emergence of issue champions both in Africa and Europe. Several respondents (I3, I4, I5 and I8) highlighted the significant role played by a Belgian academic from the Institute for Tropical Medicine, Antwerp, who had also worked at WHO. This individual, along with many students and colleagues, became influential in the STI and later HIV/AIDS communities. Their involvement extended to roles in major international organisations such as WHO, UNAIDS and the European Commission. These champions held strong authority and legitimacy due to their field experience and contacts and were able to allocate funds to STIs.

Since 2000
In 1999, the STI Unit moved back from UNAIDS to WHO, joining the newly formed Division of Reproductive Health and Research (RHR), which signalled separation between the global STI and AIDS communities. Many respondents (I1, I5, I7, I10, I17 and I20) indicated that, since 2000, the STI community has been characterised by a loose structure and lack of champions (figure 1). Although a group of policy-makers, researchers and programme managers worked closely with the WHO...
RHR, forming a club-like camaraderie to develop STI control guidelines and strategies (I2). This group was mainly research-based and had limited impact on implementation at country level (I20). Two informants believed that the withdrawal of major donors had caused a so-called ‘brain drain’ (I5 and I9), resulting in fewer young people with an interest in advocacy for STI control (I3 and I19) and personnel instability (I1 and I19) within the policy community. This has made the community less influential on the global health agenda.

...some of the best people working in STI switched to HIV...these leaders were not just scientists, but also advocates who were very vocal...I think [that] has not helped for the STI world. (I5)

Furthermore, some informants (I15, I16 and I19) perceived that, due to scarce resources, the influence of WHO could hardly go beyond the creation of technical guidelines, thus diminishing its power in shaping the priority of STI control. This situation was accentuated by the lack of new effective coordinating mechanisms, especially when contrasted with the cohesive leadership of GPA in the 1990s.

During this period, the global STI control initiative has also been marked by weak mobilisation of civil society, with some informants citing insufficient funding as a reason (I17 and I20). Only two international NGOs, the Clinton Health Access Initiative and Evidence Action, were identified during the interviews as collaborating with WHO to support some African countries in implementing PMTCT of syphilis by providing technical assistance and fixing supply chain disruptions (I12, I17, I19 and I20).

...what I’d highlight is having NGO partners that...have the capacity to support because...any time you’re sort of introducing a new service or refocusing priorities, that just requires a lot of change management and technical support. (I12)

Yet, even with the efforts of these NGOs, their reach and influence remained relatively limited in comparison to larger global health initiatives, like HIV/AIDS control.

Political contexts

Before 2000

Given the importance of HIV and its framing as a health security threat, which threatened economic and demographic stability in many parts of the world during the pre-2000 period, the initial evidence that STI control provided a solution for limiting HIV transmission provided an important policy window in the view of several respondents (I2, I3, I4, I5, I6 and I7). This window was effectively closed, with a consequent loss of attention and resources, when STI control was shown not to be effective at controlling HIV transmission (figure 1).

Since 2000

Informants did not identify specific policy windows for the broad goal of STI control since 2000. However, published studies indicated that the global goals setting in the Millennium Development Goals (MDGs) in 2000 provided an opportunity to push for a focus on individual issues such as preventing congenital syphilis, with attendant impacts on MDG 4 (reducing child mortality), 5 (improving maternal health) and 6 (combating HIV/AIDS, malaria and other diseases). Although advocates have successfully pushed for elements of STI control, such as PMTCT of syphilis, HPV vaccination and treatment for antimicrobial resistant gonorrhoea, no specific global governance mechanism for STI control was identified during the interviews. Informants did not perceive the attention on specific interventions to be able to stimulate a broader focus or prioritisation of other STIs (I19 and I20). Meanwhile, although WHO has produced a number of technical global strategies for STI control since 2000, implementation was judged to be more likely in countries with robust governance capacity and adequate funding.

The Sustainable Development Goals (SDGs) while not specifically mentioning STIs do provide opportunities to promote STI control in both SDG 5 (‘universal access to comprehensive sexual and reproductive health and reproductive rights’) and SDG 3 (‘ensuring healthy lives and promoting well-being for all’). In 2019, the United Nations General Assembly’s adoption of a new political declaration on universal health coverage (UHC), which includes commitments to increase investments in comprehensive sexual and reproductive healthcare services, may open a policy window for STIs (figure 1). According to an official from WHO:

[What] we need to do with STIs is to better integrate it into primary care and UHC...because primary care is getting some funding. And therefore, we want STIs to be seen as an essential part of primary care. (I20)

Table 3 summarises the main factors that informants mentioned as affecting the global political priority of STIs in the Shiffman and Smith framework.

DISCUSSION

Our study analyses the factors that have influenced the priority afforded to STIs by global health actors over time (figure 1). STI control was high on the global health agenda during the late 1980s and 1990s, when the world was looking for cheap, effective and feasible solutions to the HIV/AIDS epidemic, the dominant global health security concern. At that time, a strong global policy community agreed on both the high burden of STIs and the potential of STI syndromic management to reduce the incidence of new HIV infections. As indicated through informant interviews, however, the level of priority decreased when research evidence did not find an impact of STI mass treatment on HIV incidence. Since 2000, the global STI policy community has largely been characterised by a loosely organised structure, absence of champions, undefined coordinating mechanisms, lack of compelling issue framings and insufficient engagement.
of civil society. These factors, along with uncertainties surrounding the actual burden of STIs and cost-effectiveness of interventions, have contributed to challenges of achieving policy salience, with the exception of specific interventions such as PMTCT of syphilis and HPV vaccination. The global commitment to UHC from 2019 may have opened a policy window to strengthen STI control efforts within primary healthcare settings.

Our study suggests reasons for the gap between perceived and actual priority of STIs when examining the limited official development assistance allocation data. Most respondents believed that STI control had fallen off the global health agenda since the late 1990s and remarked on decreased levels of funding from major donors—responses did not appear to vary by gender identity or occupational history. This sentiment was often linked to changes in scientific evidence, with the findings of the Rakai trial and others, which broke the consensus that STI control interventions could reduce HIV transmission. Despite substantial estimates of the funds needed for broad STI control, there has been underfunding compared with more targeted initiatives, like PMTCT of syphilis, HPV vaccination and treatments for antimicrobial-resistant gonorrhoea. The disconnect between perception and evidence could result from a limited understanding of what constitutes STI control and where it is delivered. Informants talked generally about STI control without specifying infections or interventions. For instance, those focused on curable STIs might overlook the priority given to HPV vaccination as it was widely promoted as cancer prevention.

There are several limitations to the study methods. First, sample bias might have influenced beliefs about the decreased priority of STIs over time, as three quarters of respondents became engaged in STI control in the late 1980s and 1990s, a time when STIs were assigned a high priority. Informants talked generally about STI control without specifying infections or interventions. For instance, those focused on curable STIs might overlook the priority given to HPV vaccination as it was widely promoted as cancer prevention.

There are several limitations to the study methods. First, sample bias might have influenced beliefs about the decreased priority of STIs over time, as three quarters of respondents became engaged in STI control in the late 1980s and 1990s, a time when STIs were assigned a high priority. Second, respondents from LMICs were underrepresented. Our stakeholder mapping led us to a network of actors who were pivotal in STI control, predominantly from high-income countries and affiliated
with international organisations and key institutions in Europe and the USA, which reflected the decision-making landscape, particularly in the earlier decades of our study time frame. Third, there were no participants from major donors, which limited the range of views.

Our study has identified factors to consider for those seeking to boost resources for STI control. Political science suggests that a ‘policy window’ opens when three streams—policy, problem and politics—converge. There is first a need for the global STI policy community to recognise the importance of political decision-making as well as empirical evidence in driving policy attention and resource allocation. For instance, the PMTCT of syphilis programme’s alignment with MDGs 4, 5 and 6 strategically placed congenital syphilis control within a broader health and development narrative, capturing international policy attention and funding (the politics stream). This alignment, along with cost-effective interventions and concrete evidence of the global burden of congenital syphilis (the policy and problem streams, respectively), was driven by ‘political entrepreneurs’—individuals from WHO, academia and civil society. These stakeholders partnered to raise the salience of congenital syphilis, merging the three streams into a window of opportunity for increased priority.

Second, framing is crucial for political prioritisation. Control of curable STIs was prioritised when framed as a means of achieving HIV control earlier in the epidemic. The evidence that STI management did not decrease HIV transmission dealt a blow to funding for non-HIV STIs. Subsequent STI control programmes that have achieved more financial and priority ‘success’ have been framed as cancer control (HPV vaccination) and improving neonatal and maternal health (congenital syphilis control). To elevate other STIs (eg, chlamydia and gonorrhoea) on policy agendas, finding alternative framings beyond the ‘STI control’ narrative is probably necessary.

Third, action is needed to address the STI community’s apparent lack of cohesion, advocates, champions and politically strategic framings. The role of advocacy coalitions in global health is well described, particularly in the case of HIV and access to antiretroviral treatments. These coalitions derive power from their ability to bring together diverse stakeholders, leverage shared resources and create unified messages that resonate with policymakers. The field of STI control currently, however, appears to lack such cohesive and coordinated efforts beyond congenital syphilis and HPV vaccines. Initiatives to identify and engage with a range of stakeholders across civil society, reproductive health advocates, adolescent health champions, etc, are needed to foster a strong and successful advocacy movement for STI control.

Fourth, the emergence of attention to UHC around 2015, along with an ongoing emphasis on health systems strengthening, may offer new opportunities for integrating STI control into the broader health policy agenda. While UHC is essential for realising the right to health for all, limited resources necessitate priority setting to ensure fair and efficient resource allocation, especially for marginalised and vulnerable populations. Effective advocacy for global priority setting should, therefore, include diverse representation from both high-income countries and LMICs. Syndromic management and partner notification remain the primary methods for controlling curable STIs in the general population in most countries. Innovation to strengthen the development and evaluation of STI diagnostics, such as rapid multiplexed tests to detect the multiple causes of STI syndromes could improve symptom-based management at the primary healthcare level within UHC frameworks.

Lastly, recognising that official development assistance contributes only a limited part of total STI financing, and considering the frequent exclusion of STI services from essential service packages, it is crucial to take measures at national level. These should include identifying reliable funding sources, establishing strategic coordination and ensuring equitable service provision along with quality assurance.

CONCLUSION

Our study highlights the importance of recognising the political nuances in policy attention and resource allocation beyond empirical evidence, and understanding the roles that values, framing, coalitions and strategic management of evidence into processes can play. The rise of UHC since 2015 offers a promising avenue to integrate STI initiatives into broader health strategies, which will require a concerted effort to frame STI interventions appropriately (ie, framing linked to a broader agenda beyond STIs), and forge connections with other communities and stakeholders focused on sexual and reproductive health agendas.

Twitter Nicola Low @nicolamlow and Sarah J Hawkes @feminineupheave

Acknowledgements We extend our sincere gratitude to the informants who generously shared their insights and experiences, making this study possible.

Contributors NL and SH initially conceptualised the study, DW was responsible for conducting and analysing stakeholder interviews and document analysis, and regularly consulted with NL and SH during the data synthesis process. DW took the lead in drafting the manuscript, while NL and SH actively contributed to revisions for important intellectual content. All authors agreed upon the final version of the manuscript for submission. NL is guarantor for the study.

Funding This study was supported by the Swiss Network for International Studies (SNIS), Grant No.: C19063, Recipient: Nicola Low.

Competing interests None declared.

Patient and public involvement Patients and/or the public were involved in the design, conduct, or reporting, or dissemination plans of this research. Refer to the Methods section for further details.

Patient consent for publication Not applicable.

Ethics approval This study involves human participants. The Cantonal Research Ethics Committee in Bern, Switzerland (Req-2020-00269, March 2020) determined that the study was exempt from the Human Research Act, Art. 2, Paragraphs 1, Switzerland. We have uploaded the letter from the ethics committee as online supplemental file 3. Participants gave informed consent to participate in the study before taking part.

Provenance and peer review Not commissioned; externally peer reviewed.
REFERENCES


58 Mhazo AT, Maponga CC. Beyond political will: unpacking the drivers of (non) health reforms in sub-Saharan Africa. *BMJ Glob Health* 2022;7:e010228.
Online supplemental file

Understanding the factors affecting global political priority for controlling sexually transmitted infections: a qualitative policy analysis

Dadong Wu, Nicola Low, Sarah J Hawkes

Contents

Supplemental file 1a: Information sheet ................................................................. 2
Supplemental file 1b: Consent form ........................................................................... 5
Supplemental file 2: Project group members, "Political prioritisation of the prevention and control of sexually transmitted infections: a global challenge" ................................................................................................................................. 6
Supplemental file 3: Ethics waiver ............................................................................. 7
Supplemental file 1a: Information sheet

PARTICIPANT INFORMATION SHEET

Interview with key stakeholder

Please read this information sheet before you decide to take part. Please ask if there is anything that is not clear.

Title of Study:
Political prioritisation of the prevention and control of sexually transmitted infections: a global challenge

Institute:
Institute of Social and Preventive Medicine, University of Bern, Mittelstrasse 43, 3012 Bern, Switzerland

Name and Contact Details of the Researcher:
Dr Flora Dadong Wu, E-mail: dadong.wu@uzq.com or Tel.: +86(0)13823184820

Name and Contact Details of the Project Coordinator:
Professor Nicola Low, E-mail: nicola.low@ispm.unibe.ch or Tel.: +41 316313092

1. Invitation
You have been invited to take part in a research project about the political prioritisation of sexually transmitted infections (STIs) as a global health issue. Prior to deciding on whether to participate or not, it is important for you to understand why this research is being conducted and what participation will entail. Please take time to read the following information carefully and discuss it with others if you wish. Please ask the researcher if there is anything that is not clear or if you would like more information.
Take time to decide whether you wish to take part.

2. Who is organising and funding the research?
This research project is carried out by the Institute of Social and Preventive Medicine at the University of Bern and funded by the Swiss Network for International Studies.

3. What is the project’s purpose?
This research project focuses on agenda setting and policy formulation for the prevention and control of STIs as a global public health problem. The project aims to understand how, why and why not, STIs have been placed on the global policy agenda during different time periods. Through identifying the key features driving or hampering prioritisation of the issue, we seek to achieve a better understanding of the health policy process and provide recommendations for promoting STI control at both global and national levels. The study involves analyses of policy documents and media coverage, as well as in-depth interviews with key stakeholders.

4. Why have I been chosen?
We have invited you to participate in the study based on your expertise and experience in health policy. We are interviewing around 25-35 people, identified from policy documents and other experts in the field, but none of the other experts are aware that we have invited you to participate.
5. Do I have to take part?
Your participation is completely voluntary. It is up to you to decide whether or not to take part in the study. If you do agree to take part, you will be asked to sign an Informed Consent Form to confirm that you understand the purpose of the study and what is expected from you. Meanwhile, you can withdraw at any time without giving a reason (as long as it is before the results have been published). If you decide to withdraw, you will be asked what you wish to happen to the data you have provided until that point.

6. What will happen to me if I take part?
If you choose to participate in the study, we will ask you to take part in a semi-structured interview during which questions about STI policy at both global and national levels will be asked. The interview will include questions such as “How is your organisation involved in the promotion of STI control?” or “Who played a major role in shaping agenda setting for STIs?” If there are questions you do not wish to answer, you can opt out of answering them. The interview will take about 30 to 60 minutes via phone or internet call at your convenience. Your confidentiality and privacy will be ensured.

7. Will I be recorded and how will the recorded media be used?
If permission is received from you, the interview will be audio-recorded. If you prefer to not record the interview, notes will be taken by the researcher. Audio-recordings will be transcribed by the research team, and the audio-records will be deleted 3 years after the project is completed. The data will be stored locally on password-protected computers and will only be accessible by the research team.

8. Will my taking part in this project be kept confidential?
All the information that we collect about you during the course of this project will be used for the study purpose only and kept strictly confidential. You will not be personally identifiable in any ensuing reports or publications. If we use any direct quotes from your interview, we will only identify your organisation (e.g. “WHO official” or “academic”) stating no other personal features in order to avoid any possibility of you being identifiable in person. If we plan to use a (anonymised) quote from you, we will seek your permission before the findings are presented to an external audience. If you do not wish the quote to be used or information disclosed, we will not present or publish this information.

9. What will happen to the results of the research project?
The results of the study will be published as part of a project report and in peer-reviewed journals. The findings will also be presented and discussed in meetings and workshops with relevant stakeholders.

10. What are the possible disadvantages and risks of participating?
There are no direct benefits for you if you choose to participate in the study. There is a possibility of reputational risk if politically sensitive information is divulged. However, your participation will be kept unidentified to your institution and, as described earlier, you will be given an opportunity to see and approve any direct quotes used from your interview prior to presentation or dissemination of the study results. If you experience any discomfort or risk associated with your participation in the research project, please let the research team know.

11. What are the possible benefits of taking part?
There are no intended direct benefits for you from taking part in the study. However, it is hoped that the findings of the study will be relevant for promoters, policymakers, and other stakeholders working on the prevention and control of STIs.

12. What if something goes wrong?
If you have any questions arising from this Information Sheet or explanation already given to you, please ask the researcher before you decide whether to join in. Dr. Dadong Wu, Email: dadong.wu@bgs.com or Tel: +86 (0)13923184820. You will be given a copy of this Information Sheet to keep and refer to at any time.
If you have questions, concerns, or complaints, or think this research has hurt you, please contact the responsible project coordinator: Professor Nicola Low, E-mail: nicola.low@ispmp.unibe.ch or Tel.: +41 (0)316313082.

13. Ethical approval

This study is not subject to ethical committee approval in Switzerland due to the reason that it does not fall under the Swiss Human Research Act, Art. 2, Paragraph 1. The clarification of jurisdiction is presented with this Information Sheet.

Your time and cooperation is highly appreciated!
Supplemental file 1b: Consent form

I confirm that I understand that by ticking or initialling each box below, I am consenting to this element of the study. I understand that it will be assumed that unticked or initialled boxes mean that I DO NOT consent to that part of the study. I understand that by not giving consent for any one element that I may be deemed ineligible for participation in the study.

<table>
<thead>
<tr>
<th>Study element</th>
<th>Tick Box</th>
</tr>
</thead>
<tbody>
<tr>
<td>I confirm that I have read and understood the Participant Information Sheet for the above study. I have had the opportunity to consider my participation and ask questions, which have been answered to my satisfaction.</td>
<td></td>
</tr>
<tr>
<td>I consent to participate in the study as described and understand that I am free to withdraw at any time without giving a reason. I understand that if I decide to withdraw, any personal data I have provided up to that point will be deleted unless I agree otherwise.</td>
<td></td>
</tr>
<tr>
<td>The study procedures have been explained to me and I understand them. I understand that all my personal information collected will be used for the study purpose only.</td>
<td></td>
</tr>
<tr>
<td>I understand that all the data gathered in this study will be kept strictly confidential and that all efforts will be made to ensure that I cannot be identified.</td>
<td></td>
</tr>
<tr>
<td>I understand the potential risks of participating.</td>
<td>1</td>
</tr>
<tr>
<td>I understand the societal benefits of participating in research.</td>
<td>1</td>
</tr>
<tr>
<td>I understand that the information I have submitted will be published as part of a project report and in peer-reviewed journals, but I will not be identified in person, only pseudo-anonymously through my organisation.</td>
<td>1</td>
</tr>
<tr>
<td>a. I consent that written notes will be taken during my interview. (Please choose between 8a or 8b)</td>
<td></td>
</tr>
<tr>
<td>b. I consent to that my interview will be audio-recorded and I understand that the recordings will be destroyed following transcription 3 years after study completion. (Please choose between 8a or 8b)</td>
<td></td>
</tr>
<tr>
<td>I am aware of who I should contact if I wish to lodge a complaint.</td>
<td>1</td>
</tr>
<tr>
<td>I understand that the study is not subject to ethical committee approval in Switzerland, and I have read the clarification of jurisdiction.</td>
<td>1</td>
</tr>
</tbody>
</table>

Name of participant

Date

Signature

Researcher

Date

Signature

Version 2.0, 28 May 2021
Supplemental file 2: Project group members, “Political prioritisation of the prevention and control of sexually transmitted infections: a global challenge”

<table>
<thead>
<tr>
<th>Name</th>
<th>Affiliation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nicola Low</td>
<td>Institute of Social and Preventive Medicine (ISPM), University of Bern</td>
</tr>
<tr>
<td>Hira Imeri</td>
<td>Institute of Social and Preventive Medicine (ISPM), University of Bern</td>
</tr>
<tr>
<td>Eva Cignacco</td>
<td>Bern University of Applied Sciences, School of Health Professions, Midwifery Division Bern Switzerland</td>
</tr>
<tr>
<td>Sarah Hawkes</td>
<td>Institute for Global Health, University College London</td>
</tr>
</tbody>
</table>
| Dadong Wu        | Affiliated Shenzhen Maternity & Child Healthcare Hospital, Southern Medical University, Shenzhen, China  
                      | Center for World Health Organization Studies, School of Health Management of Southern Medical University, Guangzhou, China               |
| R Matthew Chico  | Department of Disease Control, Faculty of Infectious & Tropical Diseases,  
                      | London School of Hygiene and Tropical Medicine, London, United Kingdom                                                                      |
| Kelvin Kapungu   | Tropical Disease Research Centre, Ndola, Zambia                                                                                                |
| Mike Chaponda    | Tropical Disease Research Centre, Ndola, Zambia                                                                                                |
| Mae Dirac        | Institute of Health Metrics and Evaluation, University of Washington, WA, USA                                                                |
| Angela Kelly-Hanku | Papua New Guinea Institute of Medical Research, Papua New Guinea  
                          | The Kirby Institute, University of New South Wales, Sydney, Australia                                                                         |
| Lisa Valiely     | Papua New Guinea Institute of Medical Research, Papua New Guinea  
                          | The Kirby Institute, University of New South Wales, Sydney, Australia                                                                         |
| Andrew Valiely   | Papua New Guinea Institute of Medical Research, Papua New Guinea  
                          | The Kirby Institute, University of New South Wales, Sydney, Australia                                                                         |
| William Pomat    | Papua New Guinea Institute of Medical Research, Papua New Guinea                                                                          |
| Melanie Taylor   | US Centers for Disease Control and Prevention, Atlanta, Georgia, USA                                                                              |
| Jane Rowley      | Department of HIV, hepatitis and STIs, World Health Organization, Geneva, Switzerland                                                        |
| Nathalie Broutet | Department of Reproductive Health Research, World Health Organization, Geneva, Switzerland                                                    |
| Dianne Egli-Gany | Institute of Social and Preventive Medicine (ISPM), University of Bern                                                                        |
Supplemental file 3: Ethics waiver

Kanton Bern
Canton de Berne

Gesundheits-, Sozial- und Integrationsdirektion
Kantonale Ethikkommission für die Forschung

Marianistraße 31
3010 Bern
Bern
+41 31 633 70 70 (Telefon)
+41 31 633 70 71 (Telefax)
info.kas@be.ch
www.be.ch/ke

Prof. Nicola Low
University of Bern, ISPM
Mittlerestrasse 43
3012 Bern

Dorothy Pfiffner
+41 31 633 70 71
dorothy.pfiffner@be.ch

Clarification of jurisdiction

BASEC-Nr: Req-2020-00269
Date of receipt: 10/03/2020
Title: Political prioritisation of the prevention and control of sexually transmitted infections: a global challenge

Please refer to the uploaded document for a description of the project.

Result of clarification of jurisdiction

☐ Not responsible: The project is not subject to ethical committee approval in Switzerland.
Reason: The project does not fall under the Human Research Act, Art. 2, Paragraph 1.

☐ Responsible: Approval according to Human Research Act, Art. 2, Paragraph 1 is necessary in Switzerland. Please submit an application to the KEK according to www.swisseqhics.ch.

Fee: CHF 200.-- (Tariff code 6.0)

Date/Place: 23.03.2020/Bern

Prof. Dr. med. Christian Seiler
President

Dr. sc. nat. Dorothy Pfiffner
Head of the scientific secretariat